Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 34 |
| Active Pipeline (Recruiting Now) | 11 (8) |
| Completed vs Stopped Early | 3 / 0 (0.0%) |
| Median Closed Actual Enrollment | 29 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Beijing Friendship Hospital , Capital Medical University | Beijing | 19 |
| Peking Union Medical College Hospital | Beijing, Beijing Municipality | 2 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT05245474 | Neoadjuvant Long-course Chemoradiation Plus PD-1 Blockade for Mid-low Locally Advanced Rectal Cancer | Phase II | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the Beijing Friendship Hospital Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.